AUTHORS
Xinyi Tang, MD, PhD, Sujeewa Ranatunga Mahanthe Mudiyanselage, PhD2, Vaishali Bhardwaj, PhD3, Prithviraj Mukherjee, PhD, MS4, Patrizia Mondello, MD, PhD5, Zhi-Zhang Yang, MD6, Hao Xie, MD7, Stephen Maxted Ansell, MD, PhD8
AFFILIATIONS
1 Mayo Clinic, ROCHESTER, Minnesota, United States
2 Mayo Clinic, ROCHESTER, Minnesota, United States
3 Mayo Clinic, ROCHESTER, Minnesota, United States
4 Mayo Clinic, ROCHESTER, Minnesota, United States
5 Mayo Clinic, ROCHESTER, Minnesota, United States
6 Mayo Clinic, ROCHESTER, Minnesota, United States
7 Mayo Clinic, ROCHESTER, Minnesota, United States
8 Mayo Clinic, ROCHESTER, Minnesota, United States
ABSTRACT
Intratumoral regulatory T (Treg) cells represent a major barrier to effective anti-tumor immunity by suppressing cytotoxic T-cell activity. Cytokine-inducible SH2-containing protein (CISH) is a genetically validated intracellular immune checkpoint that constrains cytotoxic T-cell (CTL) and natural killer (NK) cell signaling, and emerging evidence supports a critical Treg-intrinsic role for CISH in lymphoma. Despite strong biological validation, CISH targeting has thus far been limited to genetic manipulation in adoptive cell therapies.
In this study, we sought to establish CISH as a druggable target by developing a first-in-class, cell-permeable small-molecule CISH inhibitor/degrader suitable for scalable immunotherapy development. Structure-guided small-molecule discovery was enabled by homology modeling and AlphaFold-based structural predictions of CISH, followed by the synthesis of a focused library of covalent CISH binders through systematic variation of SH2-engaging motifs and electrophilic warheads. Compounds were evaluated using thermal shift assays (TSA), mass spectrometry (MS)-based covalent engagement, cellular degradation, and signaling readouts.
Cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) identified CISH as one of the most highly expressed genes in CD26? intratumoral Tregs and confirmed that increased CISH expression is associated with poor prognosis in patients with splenic marginal zone lymphoma (SMZL). Genetic ablation or knockdown of CISH in the Treg-like KARPAS-299 cell model induced reproducible, target-dependent phenotypes, including enhanced S-phase entry and augmented STAT5 phosphorylation following IL-2 stimulation, thereby establishing rigorous cellular benchmarks for pharmacologic modulation. We then designed and synthesized more than 50 candidate CISH binders incorporating covalent SH2-domain engagement. Multiple compounds covalently bound to CISH in TSA and selectively modified Cys144, as demonstrated by mass spectrometry bioconjugation study. Introduction of a masked phosphate motif significantly improved intracellular exposure, as confirmed using a BODIPY-labeled analog. Lead compounds demonstrated cellular target engagement by cellular TSA and induced rapid, concentration-dependent degradation of endogenous CISH, while maintaining high selectivity by not degrading related SOCS family members. Functionally, lead compounds promoted KARPAS-299 cell proliferation, recapitulating a key phenotype of genetic CISH loss. Collectively, this work establishes CISH as a chemically tractable intracellular immune checkpoint and reports the development of the first selective, cell-permeable small-molecule CISH degrader.
These findings provide a strong foundation for further structure–activity relationship optimization and position CISH degradation as a promising drug-discovery strategy to modulate Treg function and enhance antitumor immunity.
DISCLOSURES
Xinyi Tang, MD, PhD: No relevant conflicts of interest to declare.